.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CRASH-3 was a large randomized trial evaluating tranexamic acid in adults with acute traumatic brain injury. The overall findings did not show a universal mortality benefit across all patients, but the study identified a more favorable effect among patients with less severe injury when treatment was given early. Importantly, tranexamic acid did not appear to produce a major excess of vascular occlusive complications in the trial population. For trauma teams, the clinical message is one of timing and patient selection rather than indiscriminate administration. Early treatment may be most useful before irreversible bleeding-related neurological injury develops, particularly in patients with mild-to-moderate traumatic brain injury. The trial also demonstrates why treatment effects in trauma can vary according to baseline severity and time from injury. Tranexamic acid should therefore be considered within the broader trauma protocol, alongside hemorrhage control, neuroimaging, airway management and definitive neurosurgical or critical-care decisions. CRASH-3 strengthened the evidence base for early antifibrinolytic therapy while illustrating the importance of applying trial findings to the right patient population.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CRASH-3 was a large randomized trial evaluating tranexamic acid in adults with acute traumatic brain injury. The overall findings did not show a universal mortality benefit across all patients, but the study identified a more favorable effect among patients with less severe injury when treatment was given early. Importantly, tranexamic acid did not appear to produce a major excess of vascular occlusive complications in the trial population. For trauma teams, the clinical message is one of timing and patient selection rather than indiscriminate administration. Early treatment may be most useful before irreversible bleeding-related neurological injury develops, particularly in patients with mild-to-moderate traumatic brain injury. The trial also demonstrates why treatment effects in trauma can vary according to baseline severity and time from injury. Tranexamic acid should therefore be considered within the broader trauma protocol, alongside hemorrhage control, neuroimaging, airway management and definitive neurosurgical or critical-care decisions. CRASH-3 strengthened the evidence base for early antifibrinolytic therapy while illustrating the importance of applying trial findings to the right patient population.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
